Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCYM9Q)

• Drug Name: XT-150 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Knee osteoarthritis	FA01	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMCYM9Q

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-10 (IL10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AM0010	DMGMNUE	Pancreatic cancer	2C10	Phase 3	[3]
Ilodecakin	DMDNHRA	Sarcoidosis	4B20.5	Phase 2	[4]
F-8-IL-10 fusion protein	DMBFPO1	Endometriosis	GA10	Phase 2	[5]
AG019	DMEN2L7	Type-1 diabetes	5A10	Phase 1/2	[6]
Ankinara	DMZKC7S	Inflammatory bowel disease	DD72	Investigative	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-10 (IL10)	TTT0Q1F	IL10_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04124042) A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Xalud Therapeutics
• [3] Clinical pipeline report, company report or official report of ARMO BioSciences.
• [4] Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58.
• [5] Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
• [6] ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health.
• [7] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.